Featured Press Releases

Moleculin's AML treatment gets EMA's Orphan Drug Designation

Moleculin's AML treatment gets EMA's Orphan Drug Designation

Formosa Pharmaceuticals Strikes Licensing Deal with Tabuk Pharmaceuticals for Clobetasol Propionate Ophthalmic Suspension

Formosa Pharmaceuticals Strikes Licensing Deal with Tabuk Pharmaceuticals for Clobetasol Propionate Ophthalmic Suspension

  • 09 May 2024

Taiwan-based Formosa Pharmaceuticals announced today that the company has entered into an...

Phanes Therapeutics' PT217 receives FDA Fast Track Designation for neuroendocrine prostate cancer (NEPC)

Phanes Therapeutics' PT217 receives FDA Fast Track Designation for neuroendocrine prostate cancer (NEPC)

Transposon to share Phase 2 results of TPN-101 for C9orf72-related ALS/FTD at ALS ONE Research Symposium.

Transposon to share Phase 2 results of TPN-101 for C9orf72-related ALS/FTD at ALS ONE Research Symposium.

Repare Therapeutics announces promising Phase 1 data showing the effectiveness of Camonsertib in combination with radiotherapy treatment

Repare Therapeutics announces promising Phase 1 data showing the effectiveness of Camonsertib in combination with radiotherapy treatment

SciTech Development reveals promising Phase 1A trial results for T-cell non-Hodgkin lymphoma therapy

SciTech Development reveals promising Phase 1A trial results for T-cell non-Hodgkin lymphoma therapy

Isotopia collaborates with LIVEKIDNEY.BIO, marking a breakthrough in lupus treatment advancements

Isotopia collaborates with LIVEKIDNEY.BIO, marking a breakthrough in lupus treatment advancements

  • Isotopia
  • 12 Dec 2024
ADC Therapeutics shares promising initial LOTIS-7 trial data on ZYNLONTA® combined with a bispecific antibody for relapsed/refractory DLBCL.

ADC Therapeutics shares promising initial LOTIS-7 trial data on ZYNLONTA® combined with a bispecific antibody for relapsed/refractory DLBCL.

  • ADC Therapeutics SA
  • 11 Dec 2024
MM+M honors Petauri's Nicole Lodowski as a 2025 40 Under 40 awardee

MM+M honors Petauri's Nicole Lodowski as a 2025 40 Under 40 awardee

  • Petauri
  • 11 Dec 2024
Pilatus Biosciences Inc. earns FDA Orphan Drug Designation for PLT012, targeting liver and intrahepatic bile duct cancer

Pilatus Biosciences Inc. earns FDA Orphan Drug Designation for PLT012, targeting liver and intrahepatic bile duct cancer

  • Pilatus Biosciences
  • 10 Dec 2024
Biolexis Therapeutics reports positive outcomes for BLX-7006 in an expanded Diet-Induced Obesity (DIO) model study

Biolexis Therapeutics reports positive outcomes for BLX-7006 in an expanded Diet-Induced Obesity (DIO) model study

  • Biolexis Therapeutics Inc
  • 09 Dec 2024
UroMems Appoints Former Axonics Executive Rinda Sama to Board of Directors

UroMems Appoints Former Axonics Executive Rinda Sama to Board of Directors

  • UroMems
  • 06 Dec 2024
The Precision Health Technologies Accelerator

Most Popular
December   2024
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31          

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.